SPS
MLTX icon

Susquehanna Portfolio Strategies’s MoonLake Immunotherapeutics MLTX Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.94M Hold
253,974
– – 0.08% 280
2026
Q1 		$4.73M Hold
253,974
– – 0.07% 314
2025
Q4 		$3.35M Buy
+253,974
New +$3M 0.05% 382

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Susquehanna Portfolio Strategies's MLTX Position: Q2 2026 in Review

Susquehanna Portfolio Strategies held its MoonLake Immunotherapeutics (MLTX) position steady in Q2 2026 at 253,974 shares worth $4.94M. The position accounts for 0.08% of the portfolio, ranked #280.

Susquehanna Portfolio Strategies first reported a position in MLTX in Q4 2025 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Susquehanna Portfolio Strategies held 253,974 shares of MoonLake Immunotherapeutics worth $4.94M as of Q2 2026.
  • Susquehanna Portfolio Strategies left its MoonLake Immunotherapeutics share count unchanged in Q2 2026.
  • MoonLake Immunotherapeutics made up 0.08% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #280 holding.
  • Susquehanna Portfolio Strategies first reported a position in MoonLake Immunotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.